An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica

Therapeutic Advances in Neurological Disorders

Volumn 9, Issue 3, 2016, Pages 180-188

  Collongues, Nicolas ^a   De Seze, Jéroˆme ^b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

B lymphocyte; CD20; monoclonal antibody; neuromyelitis optica; Rituximab

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; BETA INTERFERON; CD20 ANTIGEN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; INEBILIZUMAB; INTERFERON; METHOTREXATE; MITOXANTRONE; MONOCLONAL ANTIBODY; MYCOPHENOLATE MOFETIL; OBINUTUZUMAB; OCRELIZUMAB; OFATUMUMAB; PREDNISOLONE; RITUXIMAB;

ADD ON THERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE; CELL DESTRUCTION; COMPLEMENT DEPENDENT CYTOTOXICITY; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; HEART FAILURE; HICCUP; HUMAN; INFUSION RELATED REACTION; MACROPHAGE; MAINTENANCE THERAPY; MEDICAL RESEARCH; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NATURAL KILLER CELL; NEUTROPHIL; OPEN STUDY; OPTIC NEURITIS; PATIENT MONITORING; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; RECOMMENDED DRUG DOSE; RECURRENCE RISK; REVIEW; SEPTICEMIA; SYMPTOM; TUBERCULOSIS; VOMITING;

EID: 84962280243     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285616632653     Document Type: Review

References (53)

1. Assouline S., Buccheri V., Delmer A., Gaidano G., Mcintyre C., Brewster M., et al. (2015) Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol 80: 1001-1009.
2. Barth M., Mavis C., Czuczman M., Hernandez-Ilizaliturri F., (2015) Ofatumumab exhibits enhanced in vitro and in vivo activity compared to rituximab in pre-clinical models of mantle cell lymphoma. Clin Cancer Res 21: 4391-4397.
3. Basu B., Mahapatra T., Mondal N., (2015) Mycophenolate mofetil following rituximab in children with steroid-resistant nephrotic syndrome. Pediatrics 136: e132-e139.
4. Batchelor T., Grossman S., Mikkelsen T., Ye X., Desideri S., Lesser G., (2011) Rituximab monotherapy for patients with recurrent primary CNS lymphoma. Neurology 76: 929-930.
5. Bedi G., Brown A., Delgado S., Usmani N., Lam B., Sheremata W., (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17: 1225-1230.
6. Berger J., Neltner J., Smith C., Cambi F., (2014) Posterior reversible encephalopathy syndrome masquerading as progressive multifocal leukoencephalopathy in rituximab treated neuromyelitis optica. Mult Scler Relat Disord 3: 728-731.
7. Bologna L., Gotti E., Da Roit F., Intermesoli T., Rambaldi A., Introna M., et al. (2013) Ofatumumab is more efficient than rituximab in lysing B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 190: 231-239.
8. Boye J., Elter T., Engert A., (2003) An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 14: 520-535.
9. Capobianco M., Malucchi S., Di Sapio A., Gilli F., Sala A., Bottero R., et al. (2007) Variable responses to rituximab treatment in neuromyelitis optica (Devic's disease). Neurol Sci 28: 209-211.
10. Clifford D., Ances B., Costello C., Rosen-Schmidt S., Andersson M., Parks D., et al. (2011) Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. Arch Neurol 68: 1156-1164.
11. Collongues N., Brassat D., Maillart E., Labauge P., Ouallet J., Carra Dallière C., et al. (2015) Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler J 11 [Epub ahead of print].
12. Collongues N., De Seze J., (2011) Current and future treatment approaches for neuromyelitis optica. Ther Adv Neurol Disord 4: 111-121.
13. Cree B., Lamb S., Morgan K., Chen A., Waubant E., Genain C., (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64: 1270-1272.
14. Dass S., Rawstron A., Vital E., Henshaw K., Mcgonagle D., Emery P., (2008) Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 58: 2993-2999.
15. Davies A., Merli F., Mihaljevic B., Siritanaratkul N., Solal-Celigny P., Barrett M., et al. (2014) Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage I analysis of a randomised phase III study. Lancet Oncol 15: 343-352.
16. Flanagan E., Weinshenker B., (2014) Neuromyelitis optica spectrum disorders. Curr Neurol Neurosci Rep 14: 483.
17. Golay J., Semenzato G., Rambaldi A., Foa R., Gaidano G., Gamba E., et al. (2013) Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs 5: 826-837.
18. Greenberg B., Graves D., Remington G., Hardeman P., Mann M., Karandikar N., et al. (2012) Rituximab dosing and monitoring strategies in neuromyelitis optica patients: creating strategies for therapeutic success. Mult Scler 18: 1022-1026.
19. Harjunpaa A., Wiklund T., Collan J., Janes R., Rosenberg J., Lee D., et al. (2001) Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 42: 731-738.
20. Hultin L., Hausner M., Hultin P., Giorgi J., (1993) CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. Cytometry 14: 196-204.
21. Ip V., Lau A., Au L., Fan F., Chan A., Mok V., et al. (2013) Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci 324: 38-39.
22. Jacob A., Weinshenker B., Violich I., Mclinskey N., Krupp L., Fox R., et al. (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65: 1443-1448.
23. Jager U., Fridrik M., Zeitlinger M., Heintel D., Hopfinger G., Burgstaller S., et al. (2012) Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica 97: 1431-1438.
24. Jarius S., Aboul-Enein F., Waters P., Kuenz B., Hauser A., Berger T., et al. (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131: 3072-3080.
25. Kappos L., Li D., Calabresi P., O'Connor P., Bar-Or A., Barkhof F., et al. (2011) Ocrelizumab in relapsing-remitting multiple sclerosis: a phase II, randomised, placebo-controlled, multicentre trial. Lancet 378: 1779-1787.
26. Kavcic M., Fisher B., Seif A., Li Y., Huang Y., Walker D., et al. (2013) Leveraging administrative data to monitor rituximab use in 2875 patients at 42 freestanding children's hospitals across the United States. J Pediatr 162: 1252-1258, 1258 e1251.
27. Kim S., Huh S., Lee S., Joung A., Kim H., (2013a) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70: 1110-1117.
28. Kim S., Jeong I., Hyun J., Joung A., Jo H., Hwang S., et al. (2015) Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72: 989-995.
29. Kim S., Kim W., Li X., Jung I., Kim H., (2011) Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch Neurol 68: 1412-1420.
30. Kim S., Park J., Kim S., Park S., Kim J., Sung J., et al. (2013b) Factors associated with the time to next attack in neuromyelitis optica: accelerated failure time models with random effects. PLoS One 8: e82325.
31. Kimbrough D., Fujihara K., Jacob A., Lana-Peixoto M., Leite M., Levy M., et al. (2012) Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 1: 180-187.
32. Lampson L., (2011) Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. MAbs 3: 153-160.
33. Lindsey J., Meulmester K., Brod S., Nelson F., Wolinsky J., (2012) Variable results after rituximab in neuromyelitis optica. J Neurol Sci 317: 103-105.
34. Longoni G., Banwell B., Filippi M., Yeh E., (2014) Rituximab as a first-line preventive treatment in pediatric NMOSDs: preliminary results in 5 children. Neurol Neuroimmunol Neuroinflamm 1: e46.
35. Mahmood N., Silver K., Onel K., Ko M., Javed A., (2011) Efficacy and safety of rituximab in pediatric neuromyelitis optica. J Child Neurol 26: 244-247.
36. Mealy M., Wingerchuk D., Palace J., Greenberg B., Levy M., (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71: 324-330.
37. Mossner E., Brunker P., Moser S., Puntener U., Schmidt C., Herter S., et al. (2010) Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115: 4393-4402.
38. Muller C., Murawski N., Wiesen M., Held G., Poeschel V., Zeynalova S., et al. (2012) The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood 119: 3276-3284.
39. Nakashima I., Takahashi T., Cree B., Kim H., Suzuki C., Genain C., et al. (2011) Transient increases in anti-aquaporin-4 antibody titers following rituximab treatment in neuromyelitis optica, in association with elevated serum BAFF levels. J Clin Neurosci 18: 997-998.
40. Nasir S., Kerr D., Birnbaum J., (2009) Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus. Arch Neurol 66: 1160-1163.
41. Pellkofer H., Krumbholz M., Berthele A., Hemmer B., Gerdes L., Havla J., et al. (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76: 1310-1315.
42. Quan C., Zhangbao J., Lu J., Zhao C., Cai T., Wang B., et al. (2015) The immune balance between memory and regulatory B cells in NMO and the changes of the balance after methylprednisolone or rituximab therapy. J Neuroimmunol 282: 45-53.
43. Radaelli M., Moiola L., Sangalli F., Esposito F., Barcella V., Ferre L., et al. (2015) Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in Caucasian patients. Mult Scler 21 [Epub ahead of print].
44. Sakamoto A., Pinheiro M., Barbosa C., Fraga M., Len C., Terreri M., (2015) Rituximab use in young adults diagnosed with juvenile idiopathic arthritis unresponsive to conventional treatment: report of 6 cases. Rev Bras Reumatol 55: 536-541.
45. Salar A., Avivi I., Bittner B., Bouabdallah R., Brewster M., Catalani O., et al. (2014) Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage, phase Ib study. J Clin Oncol 32: 1782-1791.
46. Sanchez-Carteyron A., Alarcia R., Ara J., Martin J., (2010) Posterior reversible encephalopathy syndrome after rituximab infusion in neuromyelitis optica. Neurology 74: 1471-1473.
47. Teeling J., Mackus W., Wiegman L., Van Den Brakel J., Beers S., French R., et al. (2006) The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 177: 362-371.
48. Vital E., Dass S., Rawstron A., Buch M., Goeb V., Henshaw K., et al. (2010) Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 62: 1273-1279.
49. Ward E., Mittereder N., Kuta E., Sims G., Bowen M., Dall'Acqua W., et al. (2011) A glycoengineered anti-CD19 antibody with potent antibody-dependent cellular cytotoxicity activity in vitro and lymphoma growth inhibition in vivo. Br J Haematol 155: 426-437.
50. Wierda W., Padmanabhan S., Chan G., Gupta I., Lisby S., Osterborg A., et al. (2011) Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase II international study. Blood 118: 5126-5129.
51. Wingerchuk D., Lennon V., Pittock S., Lucchinetti C., Weinshenker B., (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-1489.
52. Yang C., Yang L., Li T., Zhang D., Jin W., Li M., et al. (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81: 710-713.
53. Zephir H., Bernard-Valnet R., Lebrun C., Outteryck O., Audoin B., Bourre B., et al. (2015) Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability. J Neurol 262: 2329-2335.